Globavir to seek approval and launch of novel Ebola treatment by year-end

Globavir to seek approval and launch of novel Ebola treatment by year-end


Privately-held US biotech firm Globavir Biosciences said yesterday that it intends to develop its lead…

Antibiotics and Infectious diseasesGBV006Globavir BiosciencesMarkets & MarketingPharmaceuticalRegulationRest of the WorldTropical diseasesUSA

IFPMA and the Global Fund collaborate to help protect patients from fake medicines


The International Federation of Pharmaceutical Manufacturers and Associations and the Global Fund to…

Anti-viralsAntibiotics and Infectious diseasesGlobalMarkets & MarketingPharmaceuticalRegulationTropical diseases

UNITAID market power results in price cuts of up to 80% for HIV/AIDS, TB and malaria products


UNITAID's approach to transform health product markets has delivered price reductions of up to 80% for…

Anti-viralsAntibiotics and Infectious diseasesGenericsGlobalHealthcarePharmaceuticalPricingTropical diseases

New executive director of the Global Fund outlines ambitious agenda


Mark Dybul yesterday took charge as executive director of the Global Fund to Fight AIDS, Tuberculosis…

Anti-viralsAntibiotics and Infectious diseasesFinancialManagementPharmaceuticalTropical diseases

Regulatory briefs: Amitiza in Japan; Dificid in Canada; Eurartesim roll-out


Sucampo Pharmaceuticals (Nasdaq: SCMP) and Abbott Labs (NYSE: ABT) have received approval from the Ministry…

Abbott LaboratoriesAmitizaAntibiotics and Infectious diseasesAsia-PacificDificidEurartesimGastro-intestinalsMarkets & MarketingNorth AmericaOptimer PharmaceuticalsPharmaceuticalRegulationSigma-TauSucampoTropical diseases

GlaxoSmithKline partners with BARDA to develop new class of antibiotic; amends deal with Anacor


The US Department of Health and Human Services’ Biomedical Advanced Research and Development Authority…

Anacor PharmaceuticalAntibiotics and Infectious diseasesFinancialGlaxoSmithKlineLicensingPharmaceuticalResearchTropical diseases

Back to top